PT1989200E - Compostos de pirimidinilbenzotiofeno - Google Patents

Compostos de pirimidinilbenzotiofeno Download PDF

Info

Publication number
PT1989200E
PT1989200E PT06850430T PT06850430T PT1989200E PT 1989200 E PT1989200 E PT 1989200E PT 06850430 T PT06850430 T PT 06850430T PT 06850430 T PT06850430 T PT 06850430T PT 1989200 E PT1989200 E PT 1989200E
Authority
PT
Portugal
Prior art keywords
ikk
thiophen
pyrimidin
benzo
cancer
Prior art date
Application number
PT06850430T
Other languages
English (en)
Portuguese (pt)
Inventor
Chuan Shih
Ho-Shen Lin
Michael Enrico Richett
Karl Robert Dahnke
Q May Wang
Bo Zhang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PT1989200E publication Critical patent/PT1989200E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PT06850430T 2005-11-18 2006-11-15 Compostos de pirimidinilbenzotiofeno PT1989200E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73809705P 2005-11-18 2005-11-18

Publications (1)

Publication Number Publication Date
PT1989200E true PT1989200E (pt) 2009-10-12

Family

ID=38345605

Family Applications (1)

Application Number Title Priority Date Filing Date
PT06850430T PT1989200E (pt) 2005-11-18 2006-11-15 Compostos de pirimidinilbenzotiofeno

Country Status (27)

Country Link
US (1) US7547691B2 (enExample)
EP (1) EP1989200B1 (enExample)
JP (1) JP2009516697A (enExample)
KR (1) KR100990771B1 (enExample)
CN (1) CN101309918B (enExample)
AR (1) AR057911A1 (enExample)
AT (1) ATE437873T1 (enExample)
AU (1) AU2006337626B2 (enExample)
BR (1) BRPI0618245A2 (enExample)
CA (1) CA2629336A1 (enExample)
CR (1) CR9947A (enExample)
DE (1) DE602006008187D1 (enExample)
DK (1) DK1989200T3 (enExample)
EA (1) EA014426B1 (enExample)
EC (1) ECSP088456A (enExample)
ES (1) ES2329085T3 (enExample)
IL (1) IL190489A0 (enExample)
MA (1) MA30053B1 (enExample)
NO (1) NO20082594L (enExample)
PE (1) PE20070833A1 (enExample)
PL (1) PL1989200T3 (enExample)
PT (1) PT1989200E (enExample)
SI (1) SI1989200T1 (enExample)
TN (1) TNSN08227A1 (enExample)
TW (1) TW200800201A (enExample)
WO (1) WO2007092095A2 (enExample)
ZA (1) ZA200803940B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007117399A2 (en) 2006-03-31 2007-10-18 Janssen Pharmaceutica N.V. Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor
CA2658764A1 (en) * 2006-07-20 2008-01-24 Mehmet Kahraman Benzothiophene inhibitors of rho kinase
RS51526B (sr) * 2006-12-21 2011-06-30 Eli Lilly & Company Jedinjenja imidazolidinonil aminopirimidina za lečenje kancera
CA2671738A1 (en) * 2006-12-21 2008-06-26 Eli Lilly And Company Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer
MX2009012233A (es) 2007-05-16 2009-12-01 Lilly Co Eli Compuestos de triazolil aminopirimidina.
CA2691997A1 (en) 2007-05-16 2008-11-27 Eli Lilly And Company Triazolyl aminopyrimidine compounds
EP2924025A1 (en) * 2008-06-30 2015-09-30 Janssen Pharmaceutica NV Substituted pyrimidine derivatives
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
KR101123178B1 (ko) * 2009-04-09 2012-06-13 (주)에스메디 2-아릴벤조싸이오펜 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물
BR112012003661A2 (pt) 2009-08-19 2017-04-25 Ambit Biosciences Corp "compostos de biarila e métodos de uso dos mesmos."
KR20130069641A (ko) 2010-04-27 2013-06-26 허치슨 메디파르마 리미티드 피리미디닐 인돌 화합물
US20140194383A1 (en) 2011-04-07 2014-07-10 Cornell University Monomers capable of dimerizing in an aqueous solution, and methods of using same
US9245773B2 (en) 2011-09-02 2016-01-26 Taiwan Semiconductor Manufacturing Company, Ltd. Semiconductor device packaging methods and structures thereof
CN103159742B (zh) * 2011-12-16 2015-08-12 北京韩美药品有限公司 5-氯嘧啶类化合物及其作为egfr酪氨酸激酶抑制剂的应用
AU2013216935C1 (en) 2012-02-08 2017-12-14 John Emmerson Campbell Heteroaryl compounds and methods of use thereof
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
CN105085434B (zh) * 2014-05-09 2018-02-09 上海特化医药科技有限公司 硫乙拉嗪或其中间体的制备方法
WO2017076888A1 (en) 2015-11-03 2017-05-11 Janssen Pharmaceutica Nv 2-[3-(1-methyl-piperidin-4-yl)-propylamino]-pyrimidine-5-carboxylic acids and amides and methods of making the same
MX2019000982A (es) 2016-07-29 2019-07-04 Sunovion Pharmaceuticals Inc Compuestos y composiciones y usos de los mismos.
EA201990400A1 (ru) 2016-07-29 2019-07-31 Суновион Фармасьютикалз, Инк. Соединения и композиции и их применение
WO2018140513A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
EP3573954A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
US11358959B2 (en) * 2017-01-26 2022-06-14 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
CN110869358A (zh) 2017-05-25 2020-03-06 亚瑞克西斯制药公司 Kras的共价抑制剂
CN110831933A (zh) 2017-05-25 2020-02-21 亚瑞克西斯制药公司 喹唑啉衍生物作为突变kras、hras或nras的调节剂
JP7191085B2 (ja) 2017-08-02 2022-12-16 サノビオン ファーマシューティカルズ インク イソクロマン化合物およびその使用
BR112021001709A2 (pt) 2018-08-01 2021-05-04 Araxes Pharma Llc compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer
CN113784755B (zh) 2019-03-14 2024-05-10 赛诺维信制药公司 异色满基化合物的盐及其结晶形式、制备方法、治疗用途和药物组合物
WO2026086911A1 (en) * 2024-10-24 2026-04-30 Fujian Haixi Pharmaceuticals Co., Ltd. Tyrosine kinase inhibitors and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989011279A1 (en) * 1988-05-16 1989-11-30 Georgia State University Foundation, Inc. Nucleic acid interacting unfused heteropolycyclic compounds
GB0308466D0 (en) * 2003-04-11 2003-05-21 Novartis Ag Organic compounds
JP4932735B2 (ja) * 2004-12-17 2012-05-16 アムジエン・インコーポレーテツド アミノピリミジン化合物および使用方法

Also Published As

Publication number Publication date
PL1989200T3 (pl) 2009-12-31
EA014426B1 (ru) 2010-12-30
CN101309918B (zh) 2010-12-29
KR100990771B1 (ko) 2010-10-29
CN101309918A (zh) 2008-11-19
EP1989200B1 (en) 2009-07-29
TNSN08227A1 (en) 2009-10-30
ES2329085T3 (es) 2009-11-20
BRPI0618245A2 (pt) 2011-08-23
TW200800201A (en) 2008-01-01
EP1989200A2 (en) 2008-11-12
AU2006337626A1 (en) 2007-08-16
CA2629336A1 (en) 2007-08-16
PE20070833A1 (es) 2007-08-27
ZA200803940B (en) 2009-09-30
DK1989200T3 (da) 2009-11-09
MA30053B1 (fr) 2008-12-01
US20080306082A1 (en) 2008-12-11
AU2006337626B2 (en) 2012-03-22
WO2007092095A2 (en) 2007-08-16
SI1989200T1 (sl) 2009-12-31
EA200801362A1 (ru) 2009-02-27
AU2006337626A8 (en) 2008-06-19
CR9947A (es) 2008-11-28
IL190489A0 (en) 2008-11-03
WO2007092095A3 (en) 2007-11-08
NO20082594L (no) 2008-06-10
DE602006008187D1 (de) 2009-09-10
ECSP088456A (es) 2008-06-30
US7547691B2 (en) 2009-06-16
KR20080059451A (ko) 2008-06-27
AR057911A1 (es) 2007-12-26
ATE437873T1 (de) 2009-08-15
JP2009516697A (ja) 2009-04-23

Similar Documents

Publication Publication Date Title
ZA200803940B (en) [4-(Benzo[B]thiophen-2-yl) pyrimidin-2-yl]-amine derivatives as IKK-beta inhibitors for the treatment of cancer and inflammatory diseases
AP2007004004A0 (en) Pyrrolidyl derivatives of heteroaromatic compoundsas phosphodiesterase inhibitors
PL2220030T3 (pl) Pochodne 4-(p-chinonylo)-2-hydroksybutanamidu do leczenia chorób mitochondrialnych
IL194425A0 (en) N-oxides of heterocyclic substituted bisarylureas for treating kinase-mediated diseases
IL210055A0 (en) Thiophene or thiazole derivatives and their use as pi3k inhibitors
IL195731A0 (en) Pyrimidine derivatives useful in the treatment of cancer
MX2009006706A (es) Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
IL194948A0 (en) 2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial
ZA201000075B (en) Purin derivatives for use in the treatment of fab-related diseases
IL192580A0 (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
WO2009011850A3 (en) Novel therapeutic compounds
IL193230A (en) Use of benzoxoborol derivatives in the preparation of drugs for the treatment of inflammatory diseases
IL196998A0 (en) Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
NZ602041A (en) Heterocyclic inhibitors of histamine receptors for the treatment of disease
PL2120932T3 (pl) Indazolowe pochodne jako inhibitory kinazy do leczenia raka
IL187739A0 (en) New 2-azetidinone derivatives for the treatment of hyperlipidaemic diseases
PL2321295T3 (pl) Pochodne 4-(pirydyn-4-ylo)-1H-[1,3,5]triazyn -2-onu jako inhibitory GSK2-beta do leczenia chorób degeneracyjnych
IL212716A0 (en) Thieno [3,2-c] pyridine derivatives as kinase inhibitors for use in the treatment of cancer
IL214390A0 (en) Derivatives of azapiranyl-alkylcarbamates of 5-member heterocyclic compounds, preparation thereof and therapeutic use thereof
IL206173A0 (en) 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
IL197504A0 (en) ISOSERINE DERIVATIVES AS INHIBITORS OF COAGULATION FACTOR IXa
IL197695A0 (en) 3-amino-pyridine derivatives for the treatment of metabolic disorders
IL179210A0 (en) Heterocyclic derivatives for treatment of hyperlipidemia and related diseases
ZA200901015B (en) Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
HK1123805A (en) [4-(benzo[b]thiophen-2-yl)-pyrimidin-2-yl]-amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases